Shares of Abivax tumbled as a lot 32% after it reported contemporary knowledge on its lead asset, a drug for ulcerative colitis, wiping out billions in market cap and elevating questions over how a possible takeover of the French biotech might unfold.
The medication met its endpoints of demonstrating clinically significant efficacy and a placebo-adjusted remission charge of about 40% for each doses examined, but additionally confirmed that there have been most cancers circumstances amongst sufferers taking the upper dose.
“[The] most cancers sign complicates issues,” a Jefferies analyst stated. “Even when unrelated noise, we expect the overhang will likely be actual, particularly contemplating absence of different value-inflecting knowledge occasions over the following [year].”
Within the research cohort, there was one reported case every of prostate most cancers, breast most cancers, and colonic dysplasia, which Abivax stated have been thought-about unrelated to therapy by investigators, with no organ-specific clustering noticed.
There have been additionally 4 circumstances of pores and skin most cancers on the upper 50 mg dose, of which two have been deemed not or unlikely associated to the drug, and the opposite two had a medical historical past of pores and skin most cancers, Abivax stated.
The Jefferies analysts stated that “an affordable rationalization” for the most cancers circumstances was believable however “would not seem to be an simply dismissed overhang,” and downgraded the inventory to Maintain from Purchase.
The Paris-listed inventory gained almost 1,700% in 2025, however shares had fallen 7% coming into Tuesday buying and selling.
It was final buying and selling down 31% to a completely diluted market cap of about 7 billion euros.
Abivax shares year-to-date.
The trial outcomes, printed late Monday, have been from a upkeep research during which Abivax assessed the impact of the drug, obefazimod, over 44 weeks. It comes after the outcomes of a late-stage trial in mid-2025 beat even probably the most optimistic expectations.
Analysts have described the experimental drug as a possible best-in-class therapy for ulcerative colitis (UC). Abivax can also be testing the medication for Crohn’s illness, opening it as much as a multi-billion-dollar marketplace for Irritable Bowel Syndrome (IBS).
“The novel mechanism, sustained medical remission, and favorable long-term security profile spotlight its potential to deal with a big unmet want in UC,” stated Abivax’s David Rubin, additionally director of the inflammatory bowel illness middle on the College of Chicago Medication.
“Whereas the malignancy sign can’t be ignored, we view it as a possible labelling overhang quite than proof of a transparent causal security danger,” stated Stifel analyst Damien Choplain, noting that the efficacy knowledge have been sturdy.
AbbVie’s Rinqvoc, one other medicine for ulcerative colitis and different inflammatory circumstances, carries a U.S. Meals and Drug Administration warning of malignancy however nonetheless generated $8.3 billion in gross sales in 2025, he added.
Takeover goal
Abivax has been positioned as a first-rate takeover goal, with unconfirmed rumors that large pharma has its eyes on the clinical-stage biotech led by CEO Marc de Garidel.
De Garidel advised CNBC in March that he was assured the upkeep research would learn out positively, and signaled that the corporate was in no rush to safe a deal or a partnership, as phrases could be higher after it.
It has been broadly anticipated that Abivax could be acquired earlier than launching obefazimod, and de Garidel advised CNBC that it was planning to lift cash after the June knowledge readout. The corporate on Monday reiterated the expectation to submit obefazimod for FDA approval within the fourth quarter and a possible launch in 2027.
Based on Choplain, the more than likely situation now’s that Abivax will await the total knowledge set, which is anticipated to be disclosed in October, to achieve extra granularity and ensure that the malignancies usually are not associated to the therapy.
It additionally appears cheap to imagine that potential consumers will await the total knowledge set earlier than making a transfer, he advised CNBC by way of e-mail on Tuesday.
